幽门螺杆菌感染者血清胃蛋白酶原测定的临床价值  

Clinical application of serum pepsinogen measure in persons infected helicobactor pylori

作　　者：李跃松[1] 张祥瑞[1] 殷政芳[1] 肖华龙[1] 

机构地区：[1]江苏省原子医学研究所临床部检验科,无锡214063

出　　处：《江西医学检验》2004年第3期209-210,共2页Jiangxi Journal of Medical Laboratory Sciences

摘　　要：目的研究幽门螺杆菌(HelicobactorPyolri,HP)感染者血清中胃蛋白酶原的变化及临床意义。方法对80例正常人、32例幽门螺杆菌抗体(IgG)弱阳性的可疑患者、51例幽门螺杆菌抗体阳性患者及28例治疗转阴者进行血清胃蛋白酶原Ⅰ(PepsinogenⅠ,PGⅠ)和胃蛋白酶原Ⅱ(PepsinogenⅡ,PGⅡ)的测定。结果幽门螺杆菌抗体弱阳性的可疑组、阳性组血清PGⅠ、PGⅡ的含量与对照组比较有显著性差异(P<0.05),阳性率升高,PGⅠ/PGⅡ比值明显下降(P<0.05),而治疗转阴组同对照组无差异(P>0.05)。结论通过血清PGⅠ、PGⅡ的测定可了解HP感染者的治疗情况及预后观察。Objective To study serum pepsinogen level of persons infected helicobactor pylori (HP) and its clinical application. Methods Serum pepsinogenⅠ(PGⅠ) and pepsinogenⅡ(PGⅡ) were detected in 80 normal people, 32 suspicions people with anti-HP antibod (IgG) weakly positive, 51 with anti-HP antibody positive and 28 cured cases. Results Serum PGⅠ and PGⅡ levels in of anti-HP antibody weakly positive and positive groups were higher than those of control group(P<0.05), The ratio of PGⅠ to PGⅡ was significant reduction (P<0.05), but the results of the cured cases were showed no significant differences comparing to the control group(P>0.05). Conclusion Serum PG level is valuable for the people infected HP and treating surveillance.

关 键 词：幽门螺杆菌感染 血清 胃蛋白酶原 测定 治疗 预后 

分 类 号：R573.6[医药卫生—消化系统]